These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35949044)

  • 1. A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP.
    Yu Y; Bigos KL; Marzinke MA; Landovitz RJ; McCauley M; Ford S; Hendrix CW; Bies RR; Weld ED;
    Br J Clin Pharmacol; 2022 Oct; 88(10):4623-4632. PubMed ID: 35949044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
    Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
    PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
    Brogan AJ; Davis AE; Mellott CE; Fraysse J; Metzner AA; Oglesby AK
    Pharmacoeconomics; 2024 Apr; 42(4):447-461. PubMed ID: 38267806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis.
    Durham SH; Milam A; Waer D; Chahine EB
    Ann Pharmacother; 2023 Mar; 57(3):306-316. PubMed ID: 35778802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
    Marzinke MA; Grinsztejn B; Fogel JM; Piwowar-Manning E; Li M; Weng L; McCauley M; Cummings V; Ahmed S; Haines CD; Bushman LR; Petropoulos C; Persaud D; Adeyeye A; Kofron R; Rinehart A; St Clair M; Rooney JF; Pryluka D; Coelho L; Gaur A; Middelkoop K; Phanuphak N; Cohen MS; Hendrix CW; Anderson P; Hanscom B; Donnell D; Landovitz RJ; Eshleman SH
    J Infect Dis; 2021 Nov; 224(9):1581-1592. PubMed ID: 33740057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
    Landovitz RJ; Donnell D; Clement ME; Hanscom B; Cottle L; Coelho L; Cabello R; Chariyalertsak S; Dunne EF; Frank I; Gallardo-Cartagena JA; Gaur AH; Gonzales P; Tran HV; Hinojosa JC; Kallas EG; Kelley CF; Losso MH; Madruga JV; Middelkoop K; Phanuphak N; Santos B; Sued O; Valencia Huamaní J; Overton ET; Swaminathan S; Del Rio C; Gulick RM; Richardson P; Sullivan P; Piwowar-Manning E; Marzinke M; Hendrix C; Li M; Wang Z; Marrazzo J; Daar E; Asmelash A; Brown TT; Anderson P; Eshleman SH; Bryan M; Blanchette C; Lucas J; Psaros C; Safren S; Sugarman J; Scott H; Eron JJ; Fields SD; Sista ND; Gomez-Feliciano K; Jennings A; Kofron RM; Holtz TH; Shin K; Rooney JF; Smith KY; Spreen W; Margolis D; Rinehart A; Adeyeye A; Cohen MS; McCauley M; Grinsztejn B;
    N Engl J Med; 2021 Aug; 385(7):595-608. PubMed ID: 34379922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.
    Blair CS; Li S; Chau G; Cottle L; Richardson P; Marzinke MA; Eshleman SH; Adeyeye A; Rinehart AR; Margolis D; McCauley M; Hendrix CW; Landovitz RJ;
    J Acquir Immune Defic Syndr; 2020 Sep; 85(1):93-97. PubMed ID: 32452972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
    Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
    Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
    Eshleman SH; Fogel JM; Piwowar-Manning E; Chau G; Cummings V; Agyei Y; Richardson P; Sullivan P; Haines CD; Bushman LR; Petropoulos C; Persaud D; Kofron R; Hendrix CW; Anderson PL; Farrior J; Mellors J; Adeyeye A; Rinehart A; St Clair M; Ford S; Rooney JF; Mathew CA; Hunidzarira P; Spooner E; Mpendo J; Nair G; Cohen MS; Hughes JP; Hosseinipour M; Hanscom B; Delany-Moretlwe S; Marzinke MA
    J Infect Dis; 2022 May; 225(10):1741-1749. PubMed ID: 35301540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
    Han K; Baker M; Lovern M; Paul P; Xiong Y; Patel P; Moore KP; Seal CS; Cutrell AG; D'Amico RD; Benn PD; Landovitz RJ; Marzinke MA; Spreen WR; Ford SL
    Br J Clin Pharmacol; 2022 Oct; 88(10):4607-4622. PubMed ID: 35695476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.
    Grinsztejn B; Torres TS; Hoagland B; Jalil EM; Moreira RI; O'Malley G; Shade SB; Benedetti MR; Moreira J; Simpson K; Pimenta MC; Veloso VG;
    JMIR Public Health Surveill; 2023 Apr; 9():e44961. PubMed ID: 37074775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
    Landovitz RJ; Li S; Eron JJ; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Eshleman SH; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Cohen MS; McCauley M; Hendrix CW
    Lancet HIV; 2020 Jul; 7(7):e472-e481. PubMed ID: 32497491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
    Wang W; Zhao S; Wu Y; Duan W; Li S; Li Z; Guo C; Wang W; Zhang T; Wu H; Huang X
    JMIR Public Health Surveill; 2023 Jul; 9():e46767. PubMed ID: 37498645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
    Han K; Wannamaker P; Lu H; Zhu B; Wang M; Paff M; Spreen WR; Ford SL
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0205721. PubMed ID: 35129374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
    Delany-Moretlwe S; Hughes JP; Bock P; Ouma SG; Hunidzarira P; Kalonji D; Kayange N; Makhema J; Mandima P; Mathew C; Spooner E; Mpendo J; Mukwekwerere P; Mgodi N; Ntege PN; Nair G; Nakabiito C; Nuwagaba-Biribonwoha H; Panchia R; Singh N; Siziba B; Farrior J; Rose S; Anderson PL; Eshleman SH; Marzinke MA; Hendrix CW; Beigel-Orme S; Hosek S; Tolley E; Sista N; Adeyeye A; Rooney JF; Rinehart A; Spreen WR; Smith K; Hanscom B; Cohen MS; Hosseinipour MC;
    Lancet; 2022 May; 399(10337):1779-1789. PubMed ID: 35378077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
    Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
    HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Layer Plus Approach to Implementation Research and Collaboration for Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention.
    Pilgrim NA; Evans TM; Czarnogorski M
    Health Promot Pract; 2022 Nov; 23(6):912-915. PubMed ID: 35713273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study.
    Smith JA; Garnett GP; Hallett TB
    J Infect Dis; 2021 Oct; 224(7):1179-1186. PubMed ID: 32492704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers.
    Jucker BM; Fuchs EJ; Lee S; Damian V; Galette P; Janiczek R; Macura KJ; Jacobs MA; Weld ED; Solaiyappan M; D'Amico R; Shaik JS; Bakshi K; Han K; Ford S; Margolis D; Spreen W; Gupta MK; Hendrix CW; Patel P
    Br J Clin Pharmacol; 2022 Feb; 88(4):1655-1666. PubMed ID: 34240449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.